Matthias Guckenberger, MD of University Hospital Zurich, Switzerland talks about the shifting boundary between cure and palliation. Traditionally patients with metastatic disease have been considered palliative, where there is a lower value of aggressive local radical treatment. Recently, more of these patients are classified as oligometastatic. These patients have a limited number of metastases in a limited number of origins. In these patients, it is increasingly possible to offer a curative approach with stereotactic body radiotherapy (SBRT), surgery and other techniques, and we see long-term overall survival (OS). However, patient selection must be done better to select patients which might benefit from adding local treatment to systemic treatment, and which might not benefit. Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.